Journal
BLOOD
Volume 133, Issue 16, Pages 1715-1719Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-12-852376
Keywords
-
Categories
Funding
- NCI NIH HHS [K12 CA139160] Funding Source: Medline
Ask authors/readers for more resources
Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available